New drugs for the functional cure of hepatitis B： Focusing on antisense oligonucleotides and small interfering RNAs

Xieer LIANG, Zhihong LIU, Jinlin HOU

PDF(674 KB)
PDF(674 KB)
Journal of Clinical Hepatol ›› 2025, Vol. 41 ›› Issue (1) : 7-14. DOI: 10.12449/JCH250102
Expert Forum

New drugs for the functional cure of hepatitis B： Focusing on antisense oligonucleotides and small interfering RNAs

Author information +
History +

Abstract

Existing nucleos（t）ide analogues and pegylated interferon exhibit limited efficacy in the functional cure of hepatitis B. Recently， small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， have brought unprecedented breakthroughs in the functional cure of hepatitis B with their brand-new mechanisms of action and remarkable efficacy in early clinical studies. Small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， can reduce the level of HBsAg and strive to achieve HBsAg seroclearance. The reduction in HBsAg may restore the hepatitis B-specific immune function of the body to some extent and may further transform the simple clearance of HBsAg into hard endpoints with clinical value， such as reducing hepatitis B-related liver events. By meticulously analyzing the dynamic trajectory of HBsAg alterations within the context of new drug applications and further optimizing combined treatment strategies and regimens， it is expected to transform the functional cure of hepatitis B into the ultimate goal of improving survival rates and quality of life.

Key words

Hepatitis B / Oligonucleotides， Antisense / RNA， Small Interfering / Hepatitis B Surface Antigens / Functional Cure

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Xieer LIANG , Zhihong LIU , Jinlin HOU. New drugs for the functional cure of hepatitis B： Focusing on antisense oligonucleotides and small interfering RNAs. Journal of Clinical Hepatol. 2025, 41(1): 7-14 https://doi.org/10.12449/JCH250102

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Info, 2023, 36(1): 1-17. DOI: 10.3969/j.issn.1007-8134.2023.01.01 .
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36(1): 1-17. DOI: 10.3969/j.issn.1007-8134.2023.01.01 .
本文引用 [1]
2
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021 .
本文引用 [1]
3
TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800 .
本文引用 [1]
4
FELD JJ, LOK AS, ZOULIM F. New perspectives on development of curative strategies for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2040-2050. DOI: 10.1016/j.cgh.2023.02.032 .
本文引用 [1]
5
FANNING GC, ZOULIM F, HOU JL, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0 .
本文引用 [2]
6
KIM GA, LIM YS, HAN S, et al. Viral load-based prediction of hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B: A multinational study for the development and external validation of a new prognostic model[J]. Ann Intern Med, 2024, 177(10): 1308-1318. DOI: 10.7326/M24-0384 .
本文引用 [1]
7
FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025 .
本文引用 [1]
8
YIP TCF, WONG GLH, CHAN HLY, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014 .
本文引用 [1]
9
YIP TCF, LOK ASF. How do we determine whether a functional cure for HBV infection has been achieved?[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 548-550. DOI: 10.1016/j.cgh.2019.08.033 .
本文引用 [1]
10
GHANY MG, BUTI M, LAMPERTICO P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference[J]. Hepatology, 2023, 78(5): 1654-1673. DOI: 10.1097/HEP.0000000000000431 .
本文引用 [1]
11
U. S. Food and Drug Administration. Chronic hepatitis B virus infection: developing drugs for treatment guidance for industry[EB/OL]. (2022-04-07)[2024-09-02].
https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/chronic-hepatitis-bvirus-infection-developing-drugs-treatment
本文引用 [1]
12
National Drug Administration Drug Evaluation Center. Technical guidelines for clinical trials of antiviral drugs for chronic hepatitis B[EB/OL]. (2024-04-27)[2024-09-02].
https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e
国家药品监督管理局药品审评中心. 慢性乙型肝炎抗病毒治疗药物临床试验技术指导原则[EB/OL]. (2024-04-27)[2024-09-02].
https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e
本文引用 [1]
13
MIAO YX, FU C, YU ZJ, et al. Current status and trends in small nucleic acid drug development: Leading the future[J]. Acta Pharm Sin B, 2024, 14(9): 3802-3817. DOI: 10.1016/j.apsb.2024.05.008 .
本文引用 [1]
14
YUEN MF, HEO J, JANG JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial[J]. Nat Med, 2021, 27(10): 1725-1734. DOI: 10.1038/s41591-021-01513-4 .
本文引用 [1]
15
GANE EJ, KIM W, LIM TH, et al. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection[J]. J Hepatol, 2023, 79(5): 1139-1149. DOI: 10.1016/j.jhep.2023.07.026 .
本文引用 [1]
16
HOU JL, ZHANG WH, XIE Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B[J]. N Engl J Med, 2024, 391(22): 2098-2109. DOI: 10.1056/nejmoa2405485 .
本文引用 [7]
17
FAN R, ZHAO SR, NIU JQ, et al. High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy[J]. Gut, 2024, 73(10): 1725-1736. DOI: 10.1136/gutjnl-2024-332182 .
本文引用 [3]
18
YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387(21): 1957-1968. DOI: 10.1056/NEJMoa2210027 .
本文引用 [6]
19
BUTI M, HEO J, TANAKA Y, et al. Sequential PEG-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B[J]. J Hepatol, 2025, 82(2): 222-234. DOI: 10.1016/j.jhep.2024.08.010 .
本文引用 [5]
20
DOUCETTE K, JELEV D, KAO J. Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the piranga phase 2, randomized, controlled, adaptive, open-label platform study[C]. AASLD the Liver Meeting, 2024, Abstract 5043.
本文引用 [1]
21
GANE E, LIM YS, KIM JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials[J]. J Hepatol, 2023, 79(4): 924-932. DOI: 10.1016/j.jhep.2023.05.023 .
本文引用 [1]
22
YUEN MF, LIM YS, YOON KT, et al. VIR-2218 (elebsiran) plus pegylated interferon-Alfa-2a in participants with chronic hepatitis B virus infection: A phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024, 9(12): 1121-1132. DOI: 10.1016/S2468-1253(24)00237-1 .
本文引用 [5]
23
JANSSEN HLA, HOU JL, ASSELAH T, et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection[J]. Gut, 2023, 72(7): 1385-1398. DOI: 10.1136/gutjnl-2022-328041 .
本文引用 [1]
24
VENDEVILLE S, AMBLARD F, BASSIT L, et al. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075[J]. J Med Chem, 2024, 67(23): 21126-21142. DOI: 10.1021/acs.jmedchem.4c01814 .
本文引用 [1]
25
THI EP, YE X, SNEAD NM, et al. Control of hepatitis B virus with imdusiran, a small interfering RNA therapeutic[J]. ACS Infect Dis, 2024, 10(10): 3640-3649. DOI: 10.1021/acsinfecdis.4c00514 .
本文引用 [1]
26
YUEN MF, LOCARNINI S, LIM TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB[J]. J Hepatol, 2022, 77(5): 1287-1298. DOI: 10.1016/j.jhep.2022.07.010 .
本文引用 [2]
27
GEORGE J, STEFANOVA-PETROVA D, ANTONOV K. Evaluation of the Vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: interim analysis from an open label phase 2 study[C]. AASLD the Liver Meeting, 2022, Abstract 5064.
本文引用 [1]
28
YUEN MF, ASSELAH T, JACOBSON IM, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(9): 790-802. DOI: 10.1016/S2468-1253(23)00148-6 .
本文引用 [5]
29
DONG S, WANG Z. Robust hepatitis B surface antigen reduction by ht-101 in chronic hepatitis B patients: results from a phase Ib study[J]. AASLD the Liver Meeting, 2024, Abstract 5012.
本文引用 [3]
30
DING Y, YU X, LIANG X. HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on na therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study[J]. AASLD the Liver Meeting, 2024, Abstract 5011.
本文引用 [2]
31
AGARWAL K, BUTI M, van BÖMMEL F, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2[J]. J Hepatol, 2024, 81(3): 404-414. DOI: 10.1016/j.jhep.2024.03.046 .
本文引用 [2]
32
CORNBERG M, LOK ASF, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference[J]. J Hepatol, 2020, 72(3): 539-557. DOI: 10.1016/j.jhep.2019.11.003 .
本文引用 [1]
33
MAK LY, WOODDELL CI, LENZ O, et al. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989[J]. Gut, 2024: gutjnl-gu2024-333026. DOI: 10.1136/gutjnl-2024-333026 .
本文引用 [1]
34
YUEN MF, WONG DKH, SCHLUEP T, et al. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment[J]. Gut, 2022, 71(4): 789-797. DOI: 10.1136/gutjnl-2020-323445 .
本文引用 [1]
35
TOUT I, LOUREIRO D, MANSOURI A, et al. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development[J]. J Hepatol, 2020, 73(2): 409-422. DOI: 10.1016/j.jhep.2020.04.013 .
本文引用 [1]
36
HIRODE G, CHOI HSJ, CHEN CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B study)[J]. Gastroenterology, 2022, 162(3): 757-771. e4. DOI: 10.1053/j.gastro.2021.11.002 .
37
LIM SG, TEO AE, CHAN ESY, et al. Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: A meta-analysis and meta-regression[J]. Clin Gastroenterol Hepatol, 2024, 22(12): 2403-2412. DOI: 10.1016/j.cgh.2024.05.040 .
本文引用 [1]
38
BEUDEKER BJB, OSMANI Z, van OORD GW, et al. Association of HBsAg levels with differential gene expression in NK CD8 T, and memory B cells in treated patients with chronic HBV[J]. JHEP Rep, 2023, 6(2): 100980. DOI: 10.1016/j.jhepr.2023.100980 .
本文引用 [1]
39
VERHEIJDEN S, TUEFFERD M, CRABBE M, et al. WED-372 Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients[J]. J Hepatol, 2024, 80: S810. DOI: 10.1016/S0168-8278(24)02237-2 .
本文引用 [1]
40
HOGAN T, CASTANEDA EG, GARCIA EP, et al. WED-364 High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naïve B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus nonresponders to bepirovirsen[J]. J Hepatol, 2024, 80: S807. DOI: 10.1016/S0168-8278(24)02231-1 .
本文引用 [1]
41
BERG T, SIMON KG, MAUSS S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study[J]. J Hepatol, 2017, 67(5): 918-924. DOI: 10.1016/j.jhep.2017.07.012 .
本文引用 [1]
42
HOU J, XIE Q, ZHANG W. Outcomes of nucleos(t)ide analogue discontinuation in chronic hepatitis B participants treated with xalnesiran with and without an immunomodulator: 48 weeks of follow-up results from the phase 2, randomized, controlled, adaptive, open-label platform study piranga[J]. AASLD the Liver Meeting, 2024, Abstract 252.
本文引用 [1]

南方医科大学南方医院感染内科为本研究第一完成单位。梁携儿负责研究设计，文章撰写；梁携儿、刘智泓参与研究数据/信息的收集与解读分析；侯金林、梁携儿负责文章提纲与全文审核。

Funding

National Key R & D Program of China(2022YFC2304800)

Comments

PDF(674 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Clinical Hepatol, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉